KR100769579B1 - Cosmetic composition for improving skin wrinkles - Google Patents
Cosmetic composition for improving skin wrinkles Download PDFInfo
- Publication number
- KR100769579B1 KR100769579B1 KR1020030081596A KR20030081596A KR100769579B1 KR 100769579 B1 KR100769579 B1 KR 100769579B1 KR 1020030081596 A KR1020030081596 A KR 1020030081596A KR 20030081596 A KR20030081596 A KR 20030081596A KR 100769579 B1 KR100769579 B1 KR 100769579B1
- Authority
- KR
- South Korea
- Prior art keywords
- cosmetic composition
- skin wrinkles
- skin
- composition
- xanthotoxol
- Prior art date
Links
- 230000037303 wrinkles Effects 0.000 title claims abstract description 71
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 239000002537 cosmetic Substances 0.000 title claims abstract description 42
- JWVYQQGERKEAHW-UHFFFAOYSA-N xanthotoxol Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2O JWVYQQGERKEAHW-UHFFFAOYSA-N 0.000 claims abstract description 53
- YXCORZFYRFZUOV-UHFFFAOYSA-N Xanthotoxol Natural products COc1c2OC(O)C=Cc2cc3ccoc13 YXCORZFYRFZUOV-UHFFFAOYSA-N 0.000 claims abstract description 36
- GIJHDGJRTUSBJR-UHFFFAOYSA-N Bergaptol Natural products O1C(=O)C=CC2=C1C=C1OC=CC1=C2O GIJHDGJRTUSBJR-UHFFFAOYSA-N 0.000 claims abstract description 31
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 238000009472 formulation Methods 0.000 claims description 6
- -1 pack Substances 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 239000002585 base Substances 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 239000000686 essence Substances 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 239000008234 soft water Substances 0.000 claims description 2
- 230000000475 sunscreen effect Effects 0.000 claims description 2
- 239000000516 sunscreening agent Substances 0.000 claims description 2
- 239000004816 latex Substances 0.000 claims 1
- 229920000126 latex Polymers 0.000 claims 1
- 230000006872 improvement Effects 0.000 abstract description 34
- 108010035532 Collagen Proteins 0.000 abstract description 31
- 102000008186 Collagen Human genes 0.000 abstract description 31
- 229920001436 collagen Polymers 0.000 abstract description 31
- 230000000694 effects Effects 0.000 abstract description 21
- 230000015572 biosynthetic process Effects 0.000 abstract description 17
- 238000003786 synthesis reaction Methods 0.000 abstract description 17
- 210000002950 fibroblast Anatomy 0.000 abstract description 9
- 230000037394 skin elasticity Effects 0.000 abstract description 5
- 210000003491 skin Anatomy 0.000 description 69
- 230000000052 comparative effect Effects 0.000 description 20
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000010191 image analysis Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000036570 collagen biosynthesis Effects 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002436 one-dimensional nuclear magnetic resonance spectrum Methods 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 239000008278 cosmetic cream Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 238000011891 EIA kit Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000001153 anti-wrinkle effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000002026 chloroform extract Substances 0.000 description 2
- 239000002036 chloroform fraction Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000401 methanolic extract Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000004215 skin function Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- KWZYQHQNOWRQRG-UHFFFAOYSA-N 3beta-hydroxytremetone Natural products C1=C(C(C)=O)C=C2C(O)C(C(=C)C)OC2=C1 KWZYQHQNOWRQRG-UHFFFAOYSA-N 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 241000123841 Angelica dahurica var. formosana Species 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- 235000014493 Crataegus Nutrition 0.000 description 1
- 241001092040 Crataegus Species 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical group C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KWZYQHQNOWRQRG-OLZOCXBDSA-N Toxol Chemical compound C1=C(C(C)=O)C=C2[C@@H](O)[C@H](C(=C)C)OC2=C1 KWZYQHQNOWRQRG-OLZOCXBDSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- PCWZKQSKUXXDDJ-UHFFFAOYSA-N Xanthotoxin Natural products COCc1c2OC(=O)C=Cc2cc3ccoc13 PCWZKQSKUXXDDJ-UHFFFAOYSA-N 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 238000004141 dimensional analysis Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000002044 hexane fraction Substances 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960004469 methoxsalen Drugs 0.000 description 1
- SQBBOVROCFXYBN-UHFFFAOYSA-N methoxypsoralen Natural products C1=C2OC(=O)C(OC)=CC2=CC2=C1OC=C2 SQBBOVROCFXYBN-UHFFFAOYSA-N 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 피부 주름 개선용 화장료 조성물에 관한 것으로서, 더욱 상세하게는 잔토톡솔(Xanthotoxol: 8-hydroxypsoralen)을 유효성분으로 포함하는 피부 주름 개선용 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition for improving skin wrinkles, and more particularly, to a cosmetic composition for improving skin wrinkles including xanthotoxol (8-hydroxypsoralen) as an active ingredient.
본 발명의 피부 주름 개선용 화장료 조성물은 피부의 섬유아세포의 콜라겐 합성을 촉진함으로써, 피부의 탄력을 향상시키고 주름을 개선하는 효과가 매우 우수하다.The cosmetic composition for improving skin wrinkles of the present invention promotes collagen synthesis of fibroblasts of the skin, and thus has an excellent effect of improving skin elasticity and improving wrinkles.
잔토톡솔, 콜라겐, 피부 주름 개선, 화장료Xantoxol, collagen, skin wrinkle improvement, cosmetics
Description
도 1은 본 발명의 실시예 1에서 얻어진 잔토톡솔(Xanthotoxol: 8-hydroxypsoralen)에 대한 1H-1D NMR 스펙트럼 결과이고,1 is a 1 H-1D NMR spectrum of Xanthotoxol (8-hydroxypsoralen) obtained in Example 1 of the present invention,
도 2는 본 발명의 실시예 1에서 얻어진 잔토톡솔(Xanthotoxol: 8-hydroxypsoralen)에 대한 13C-1D NMR 스펙트럼 결과이고,2 is a 13 C-1D NMR spectrum of Xanthotoxol (8-hydroxypsoralen) obtained in Example 1 of the present invention,
도 3은 본 발명의 실시예 1에서 얻어진 잔토톡솔(Xanthotoxol: 8-hydroxypsoralen)의 Mass 스펙트럼 결과이다.3 is a mass spectrum result of xanthotoxol (8-hydroxypsoralen) obtained in Example 1 of the present invention.
[산업상 이용분야][Industrial use]
본 발명은 피부 주름 개선용 화장료 조성물에 관한 것으로서, 더욱 상세하게는 피부의 섬유아세포의 콜라겐합성을 촉진하여 피부의 탄력을 향상시키고, 피부 주름을 개선하는 효과가 우수한 피부 주름 개선용 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition for improving skin wrinkles, and more particularly, to a skin composition for improving skin wrinkles by promoting collagen synthesis of fibroblasts of the skin to improve skin elasticity and improving skin wrinkles. will be.
[종래기술] [Private Technology]
세포 외 기질(matrix)의 주요 구성 성분인 콜라겐은 피부의 섬유아세포에서 생성되는 주요 기질 단백질로서 세포 외 간질에 존재한다. 또한, 생체 단백질 총 중량의 약 30%를 차지하는 중요한 단백질로서 견고한 3중 나선구조를 가지고 있다. 콜라겐은 피부, 건(tendon), 뼈 및 치아의 유기 물질의 대부분을 형성하는데, 특히 뼈와 피부 (진피)에 그 포함량이 높다. 대부분의 다른 체 구조물에서는 섬유상 봉입체로서 존재한다.Collagen, a major component of the extracellular matrix, is present in the extracellular epilepsy as a major matrix protein produced by skin fibroblasts. It is also an important protein, accounting for about 30% of the total weight of biological proteins, and has a solid triple helix structure. Collagen forms most of the organic material of the skin, tendons, bones and teeth, especially in bones and skin (dermis). Most other sieve structures exist as fibrous inclusions.
콜라겐은 비교적 약한 면역원인데, 콜라겐의 나선 구조에 의한 잠재성 항원 결정인자의 차폐가 그 일부 원인이고, 이 나선 구조는 또한 콜라겐이 단백질 분해에 대한 내성을 갖도록 한다. 콜라겐의 주된 기능으로는 피부의 기계적 견고성, 결합조직의 저항력과 조직의 결합력, 세포 접착의 지탱, 세포 분할과 분화(유기체의 성장 혹은 상처 치유 시)의 유도 등이 알려져 있다(Van der Rest 등, 1990). 이러한 콜라겐은 연령 및 자외선 조사에 의한 광노화에 의해 감소하며, 이는 피부의 주름 형성과 밀접한 연관이 있다고 알려져 있다(Arthur K. Balin et al., “Aging and the skin”, 1989). 또한 근래에 들어 피부 노화에 대한 광범위한 연구가 발전되면서 피부에서의 콜라겐의 중요한 기능이 밝혀지고 있다.Collagen is a relatively weak immunogen, partly due to the shielding of latent antigenic determinants by the helix structure of collagen, which also makes collagen resistant to proteolysis. The main functions of collagen are known as mechanical firmness of skin, resistance of connective tissue and binding of tissue, support of cell adhesion, induction of cell division and differentiation (when organic growth or wound healing) (Van der Rest et al., 1990). This collagen is reduced by age and photoaging by UV irradiation, which is known to be closely related to wrinkle formation of the skin (Arthur K. Balin et al., “Aging and the skin”, 1989). In recent years, extensive research on aging of the skin has been developed to reveal the important function of collagen in the skin.
종래에는 콜라겐의 피부 보습 효과를 이용하기 위하여 화장품 등에 콜라겐을 배합한 제품들이 출시되어 있으나, 이들 화장품 등은 콜라겐을 피부 표면에 도포하는 것으로서 고분자 물질인 콜라겐의 경피 흡수가 어려워 보습작용을 기대할 수 없으므로 본질적인 피부 기능 개선이라고 말할 수 없었다.Conventionally, products using collagen have been released in order to take advantage of collagen's skin moisturizing effect.However, these cosmetics apply collagen to the surface of the skin. It could not be said to be an essential skin function improvement.
이러한 문제를 해결하기 위하여 콜라겐 합성 촉진 물질에 대한 관심이 높아 졌으며, 종래에 알려진 콜라겐 합성 촉진 물질로는 레티노익산(retinoic acid), 발암증식인자(TGF : transforming growth factor)(Cardinale G. et al, Adv. Enzymol., 41, p. 425, 1974), 동물 태반 유래의 단백질(일본특개평 8-231370), 베툴린산(betulinic acid)(일본특개평 8-208424), 클로렐라 추출물(일본특개평 9-40523, 일본특개평 10-36283, 섬유아세포 증식 촉진작용) 등이 있다.In order to solve this problem, interest in collagen synthesis promoting material has been increased, and conventionally known collagen synthesis promoting materials include retinoic acid and transforming growth factor (TGF) (Cardinale G. et al, Adv.Enzymol., 41, p.425, 1974), protein from animal placenta (Japanese Patent Laid-Open No. 8-231370), betulinic acid (Japanese Patent Laid-Open No. 8-208424), chlorella extract (Japanese Laid-Open Patent No. 9) -40523, Japanese Patent Laid-Open No. 10-36283, fibroblast proliferation promoting action).
그러나, 이들 물질은 피부에 적용 시 자극과 발적 등의 안전성의 문제로 사용량의 제한이 있거나 효과가 미미하여 실질적으로 피부 기능 개선 효과를 기대할 수 없다. 따라서, 기존의 피부 주름 개선 화장료 조성물보다 생체에 안전하고 효과가 높은 새로운 피부 주름 개선용 화장료 조성물의 개발이 절실히 요망되고 있다.However, these substances have limited use or insignificant effects due to safety problems such as irritation and redness when applied to the skin, and thus, the effect of improving skin function cannot be expected. Therefore, there is an urgent need for the development of a new skin wrinkle improvement cosmetic composition that is safer and more effective in vivo than the existing skin wrinkle improvement cosmetic composition.
상기와 같은 종래의 문제점을 해결하기 위하여, 본 발명의 목적은 생체에 안전할 뿐 아니라 콜라겐의 합성을 촉진하여 피부의 탄력을 향상시키고, 피부 주름을 개선하는 효과가 우수한 콜라겐 합성 촉진제를 제공하는 것이다.In order to solve the conventional problems as described above, an object of the present invention is to provide a collagen synthesis promoter having an excellent effect of improving the elasticity of the skin by improving the synthesis of collagen, as well as safe to the living body. .
본 발명의 또 다른 목적은 생체에 안전할 뿐 아니라 콜라겐의 합성을 촉진하여 피부의 탄력을 향상시키고, 피부 주름을 개선하는 효과가 우수한 피부 주름 개선용 화장료 조성물을 제공하는 것이다.Still another object of the present invention is to provide a cosmetic composition for improving skin wrinkles, which is not only safe for a living body but also promotes synthesis of collagen to improve skin elasticity and improve skin wrinkles.
상기 목적을 달성하기 위하여, 본 발명은 하기 화학식 1로 표시되는 잔토톡솔(Xanthotoxol: 8-Hydoxypsoralen)을 유효성분으로 포함하는 콜라겐 합성 촉진제 를 제공한다.In order to achieve the above object, the present invention provides a collagen synthesis promoter comprising xanthotoxol (8-Hydoxypsoralen) represented by the following formula (1) as an active ingredient.
[화학식 1][Formula 1]
또한, 본 발명은 상기 화학식 1로 표시되는 잔토톡솔(Xanthotoxol : 8-hydroxypsoralen)을 유효성분으로 포함하는 피부 주름 개선용 화장료 조성물을 제공한다.In addition, the present invention provides a cosmetic composition for improving skin wrinkles comprising xanthotoxol (Xanthotoxol: 8-hydroxypsoralen) represented by
이하, 본 발명을 상세하게 설명한다.EMBODIMENT OF THE INVENTION Hereinafter, this invention is demonstrated in detail.
본 발명자들은 피부 주름 개선용 화장료 조성물의 유효성분으로서 우수한 콜라겐 합성 촉진 효과를 갖는 물질을 개발하던 중, 화학식 1의 잔토톡솔이 매우 강력한 콜라겐 합성촉진 효과가 있음을 밝혀내고, 본 발명을 완성하게 되었다. 본 발명에서 유효성분으로 사용되는 잔토톡솔의 콜라겐 합성능 및 피부 주름 개선효과에 관해서는 기존의 어떠한 연구도 없었다.The inventors of the present invention, while developing a substance having an excellent collagen synthesis promoting effect as an active ingredient of the cosmetic composition for improving skin wrinkles, found that xantoxoxol of Formula 1 has a very strong collagen synthesis promoting effect, and completed the present invention. . There is no previous study on the collagen synthesis ability and skin wrinkle improvement effect of the xanthotosol used as an active ingredient in the present invention.
본 발명의 상기 화학식 1의 잔토톡솔은 생체에 안전하고 피부의 섬유아세포의 콜라겐 합성을 촉진하는 콜라겐 합성 촉진제로 사용되고 피부의 탄력을 향상시키고 피부 주름 개선효과도 매우 우수하다.Xanthotoxol of the formula (1) of the present invention is used as a collagen synthesis promoter to promote the collagen synthesis of fibroblasts of the skin safe to the living body and improve the elasticity of the skin and also very good skin wrinkle improvement.
천연상태의 잔토톡솔은 주로 산형목과 식물의 뿌리에 존재하는 화합물이다. 잔토톡솔을 얻을 수 있는 방법으로는 여러 가지가 있을 수 있다. 예를 들면 산형목과 식물인 구릿대의 뿌리(백지)를 잘게 잘라서 물, 탄소수 1 내지 4의 무수 또는 함수 저급 알코올, 에틸아세테이트, 아세톤, 클로로포름 또는 이들의 혼합물을 첨가하여 가온 추출하고, 용매분획한 후 재결정화함으로써 얻을 수 있다. 본 발명은 NMR 및 Mass 스펙트럼 분석 결과를 통하여 추출물이 하기 화학식 1의 잔토톡속임을 동정할 수 있다.Xanthotoxol in its natural state is a compound mainly found in hawthorn and roots of plants. There are many ways to get xantoxol. For example, finely chopped roots (white paper) of hawthorns and plants, added with water, anhydrous or hydrous lower alcohols having 1 to 4 carbon atoms, ethyl acetate, acetone, chloroform or a mixture thereof, and extracted by heating, and solvent fractionation. Obtained by recrystallization. The present invention can identify that the extract is Xantho toxin of the formula (1) through the results of NMR and Mass spectrum analysis.
[화학식 1][Formula 1]
본 발명의 콜라겐 합성 촉진제의 유효성분으로 포함되는 잔토톡솔의 함량은 0.00001 내지 5 중량%로 포함되거나 전체함량으로도 포함될 수 있으며 유효함량 범위이면 특별히 한정되지는 않는다. 또한, 본 발명의 화합물은 여러 가지 경구 또는 비경구 방법으로 투여될 수 있으며, 약리학적으로 허용가능한 액체 또는 고체 담체를 더욱 포함할 수 있다.Xantho toxol content included as an active ingredient of the collagen synthesis promoter of the present invention may be included in 0.00001 to 5% by weight or may be included as a total content is not particularly limited as long as the effective content range. In addition, the compounds of the present invention may be administered by various oral or parenteral methods, and may further include a pharmaceutically acceptable liquid or solid carrier.
또한, 본 발명은 상기 화학식 1의 잔토톡솔을 유효성분으로 포함하는 피부 주름 개선용 화장료 조성물을 제공한다. 본 발명의 조성물은 인체에 적용하여도 독성이 없으며 우수한 피부의 탄력과 피부주름개선 효과를 얻을 수 있다.In addition, the present invention provides a cosmetic composition for improving skin wrinkles comprising xantoxoxol of Formula 1 as an active ingredient. The composition of the present invention is not toxic even if applied to the human body can obtain an excellent skin elasticity and wrinkle improvement effect.
본 발명의 피부주름 개선용 화장료 조성물은 잔토톡솔을 전체 조성물 중량에 대하여 0.000001 중량% 내지 10 중량%로 포함할 수 있으며, 보다 바람직하게는 0.001 내지 10 중량%, 가장 바람직하게는 0.1 중량% 내지 10 중량%로 포함할 수 있다. 상기 잔토톡솔의 함량이 0.000001 중량% 미만인 경우에는 뚜렷한 효과를 기대할 수 없고, 10 중량%를 초과하는 경우에는 포함량의 증가에 비해 효과의 증가가 미치지 못한다.The cosmetic composition for improving skin wrinkles of the present invention may include xanthotoxol in an amount of 0.000001 wt% to 10 wt% with respect to the total weight of the composition, more preferably 0.001-10 wt%, most preferably 0.1 wt% to 10 wt%. It may be included in weight percent. When the content of the xanthotoxol is less than 0.000001% by weight, no obvious effect can be expected, and when it exceeds 10% by weight, the effect does not increase as compared with the increase in the amount of inclusion.
본 발명에 따른 피부주름 개선용 화장료 조성물은 외용연고, 크림, 폼, 화장수, 팩, 유연수, 유액, 파운데이션, 메이크업베이스, 엣센스, 비누, 액체세정료, 입욕제, 선 스크린크림, 또는 선오일 등의 제형으로 제조할 수 있다.The cosmetic composition for improving skin wrinkles according to the present invention is an external ointment, cream, foam, lotion, pack, soft water, emulsion, foundation, makeup base, essence, soap, liquid cleanser, bathing agent, sunscreen cream, or sun oil It may be prepared in a dosage form.
또한, 본 발명의 화장료 조성물은 일반 피부화장료에 배합되는 약리학적으로 허용 가능한 담체를 1 종 이상 추가로 포함할 수 있으며, 통상의 성분으로 예를 들면 유분, 물, 계면활성제, 보습제, 저급알콜, 증점제, 킬레이트제, 색소, 방부제, 향료 등을 적절히 배합할 수 있다.In addition, the cosmetic composition of the present invention may further include one or more pharmacologically acceptable carriers formulated in general skin cosmetics, and as conventional components, for example, oil, water, surfactants, moisturizers, lower alcohols, Thickeners, chelating agents, colorants, preservatives, fragrances and the like can be appropriately blended.
이하 본 발명의 이해를 돕기 위하여 바람직한 실시 예를 제시하나, 하기 실시 예는 본 발명을 예시하는 것일 뿐 본 발명의 범위가 하기 실시 예에 한정되는 것은 아니다. Hereinafter, preferred examples are provided to help understanding of the present invention, but the following examples are merely to illustrate the present invention, and the scope of the present invention is not limited to the following examples.
[실시예 1]Example 1
잔토톡솔의 추출Extraction of Xanthotoxol
1-1. 메탄올을 이용한 잔토톡솔의 추출1-1. Extraction of Xanthotosol Using Methanol
백지(Angelica dahurica 또는 Angelica dahurica var. formosana)의 건조된 뿌리 1kg을 메탄올 10 리터에 넣고, 환류 냉각기가 달린 추출기에서 80 ℃로 3시간 가온 추출하여 85 g의 메탄올 추출액을 얻었다. 상기 메탄올 추출액으로부터 용매분획을 통하여 헥산 분획을 제거하고 얻어진 분획을 클로로포름으로 3회 분획하여 9 g의 클로로포름 분획을 얻었다. 상기 얻어진 클로로포름 분획을 수회에 걸쳐 실 리카 컬럼 크로마토 그라피(Silica column chromatography)를 통하여 잔토톡솔을 포함하는 분획 0.3 g을 얻었고, 이 분획을 분취용 HPLC(Prep-HPLC) 및 재결정 방법을 이용하여 하기 화학식 1의 잔토톡솔을 얻었다. 상기 방법으로 얻은 잔토톡솔은 NMR과 질량 분광계(Mass spectroscopy)를 통하여 성분과 함량(99.7 중량%)을 확인하였다. 상기 NMR 스펙트럼은 도 1(1H-1D NMR 스펙트럼) 및 도 2(13C-1D NMR 스펙트럼)에 나타내었으며, 상기 Mass 스펙트럼(MS 및 MS/MS)은 도 3에 나타내었다.1 kg of dried roots of white paper (Angelica dahurica or Angelica dahurica var. Formosana) were placed in 10 liters of methanol and extracted by heating at 80 ° C. for 3 hours in an extractor equipped with a reflux condenser to obtain 85 g of methanol extract. The hexane fraction was removed from the methanol extract through a solvent fraction, and the obtained fraction was fractionated three times with chloroform to obtain 9 g of chloroform fraction. The obtained chloroform fraction was subjected to silica column chromatography several times to obtain 0.3 g of a fraction containing xanthoxol, which was then purified by preparative HPLC (Prep-HPLC) and recrystallization. A xanthoxol of 1 was obtained. Xanthotoxol obtained by the above method was identified by NMR and mass spectroscopy to determine the composition and content (99.7% by weight). The NMR spectrum is shown in FIG. 1 ( 1 H-1D NMR spectrum) and FIG. 2 ( 13 C-1D NMR spectrum), and the mass spectra (MS and MS / MS) are shown in FIG. 3.
[화학식 1][Formula 1]
1-2. 클로로포름을 이용한 잔토톡솔 추출1-2. Xantho Toxol Extraction Using Chloroform
백지의 건조된 뿌리 1kg을 클로로포름 10 리터에 넣고 환류냉각기가 달린 추출기에서 100 ℃로 3시간 가온 추출하여 클로로포름 추출액 12 g을 얻었다. 상기 클로로포름 추출액을 클로로포름에 녹이고 알카리 수용액(0.1M NaOH 수용액)으로 용매분획하여 알카리수용액 가용부를 얻은 후, HCl로 중화시키고 클로로포름으로 용매분획하여 얻은 클로로포름 분획 1 g을 분취용 HPLC(Prep-HPLC) 및 재결정 방법을 이용하여 잔토톡솔을 얻었다. 상기 방법으로 얻은 잔토톡솔은 NMR과 질량 분광계(Mass spectroscopy)를 통하여 성분과 함량(99.7 중량%)을 확인하였다.1 kg of dried root of white paper was placed in 10 liters of chloroform, and extracted by heating at 100 ° C. for 3 hours in an extractor equipped with a reflux condenser to obtain 12 g of chloroform extract. The chloroform extract was dissolved in chloroform, and the solvent was fractionated with an alkaline aqueous solution (0.1 M NaOH aqueous solution) to obtain an aqueous alkaline solution, followed by neutralization with HCl and solvent fractionation with chloroform. Xanthotoxol was obtained using the recrystallization method. Xanthotoxol obtained by the above method was identified by NMR and mass spectroscopy to determine the composition and content (99.7% by weight).
[실시예 2] Example 2
잔토톡솔의 콜라겐 생합성 효과Collagen Biosynthesis Effect of Xanthotoxol
잔토톡솔을 인간유래의 섬유아세포의 배양액에 첨가하여 세포수준에서 피부 주름 개선용 화장료 효과를 실험하였다. 생합성된 콜라겐의 측정은 PICP EIA kit(Procollagen Type I C-Peptide Enzyme ImmunoAssay KIT)를 이용하여 정량하였다.Xanthotoxol was added to the culture solution of human-derived fibroblasts, and the cosmetic effect for skin wrinkle improvement at the cellular level was tested. Biosynthetic collagen was measured using a PICP EIA kit (Procollagen Type I C-Peptide Enzyme ImmunoAssay KIT).
잔토톡솔은 최종농도 0.5 ㎍/ml, 1 ㎍/ml, 2 ㎍/ml, 5 ㎍/ml, 10 ㎍/ml가 되도록 하여 비타민 C와 대조군과 함께 각각 인간 유래의 섬유아세포(human fibroblast세포)의 배양배지에 첨가하여 1일간 배양한 후, 배양액을 취하여 PICP EIA Kit로 각 농도에서 콜라겐 생합성 정도를 분광광도계를 이용하여 450nm에서 측정하였다. 콜라겐 생합성능은 대조군(무첨가)에 대한 상대적인 합성능으로 계산하고 결과를 표 1에 정리하였다.Xanthotosol is 0.5 μg / ml, 1 μg / ml, 2 μg / ml, 5 μg / ml, and 10 μg / ml in final concentrations of human fibroblast cells. After adding to the culture medium and incubating for one day, the culture medium was taken, and the degree of collagen biosynthesis at each concentration was measured at 450 nm using a spectrophotometer with PICP EIA Kit. Collagen biosynthesis was calculated as the relative synthetic ability relative to the control (no addition) and the results are summarized in Table 1.
상기 표 1의 결과에서 볼 수 있듯이, 본 발명의 잔토톡솔은 인간유래의 섬유아세포에 대하여 우수한 콜라겐 생합성능이 있으며, 일반적으로 콜라겐 합성 능력이 있는 것으로 알려진 비타민 C를 적용한 경우보다 적은 농도로 더 우수한 콜라겐 합성 효과를 얻을 수 있음을 알 수 있다. As can be seen from the results of Table 1, the xanthotoxol of the present invention has excellent collagen biosynthesis performance against human-derived fibroblasts, and generally better collagen at a lower concentration than when vitamin C is known to have collagen synthesis ability. It can be seen that a synthetic effect can be obtained.
[실시예 3]Example 3
잔토톡솔의 피부 주름개선 효과Anti-wrinkle Effect of Xantho Toxol
6주령의 헤어리스 마우스를 이용하여 광에 의해 유발된 피부 주름에 대하여 잔토톡솔의 피부 주름개선 효과를 시험하였다. 시료는 잔토톡솔을 1,3-부틸렌글리콜에 5 mg/ml로 녹여 적용하였다. 헤어리스 마우스에 태양광 조사기(solar simulator)를 이용하여 2 MED로 1주일에 3일 10주간 조사하여 피부 주름을 형성시키고, 시료를 첨가하지 않은 1,3-부틸렌글리콜을 처리한 대조군과 5 mg/ml의 잔토톡솔 용액을 1일 2회 0.5 ml/㎠(잔토톡솔로 2.5 mg/㎠)씩 6주간 처리한 군을 대상으로 개선 정도를 정성 판단하였다.A 6-week-old hairless mouse was used to test the anti-wrinkle effect of xanthotoxol against light-induced skin wrinkles. The sample was applied by dissolving xanthotosol in 1,3-butylene glycol at 5 mg / ml. Hairless mice were irradiated with 2 MED for 3 days and 10 weeks a day using a solar simulator to form skin wrinkles, and the control treated with 1,3-butylene glycol without addition of the sample and 5 The improvement degree was qualitatively determined in the group treated with 0.5 ml / cm 2 (2.5 mg / cm 2 with xanthotoxol) of mg / ml xanthotoxol solution twice daily.
주름개선 정도의 판단은 먼저 시료 처리 부위를 육안과 사진 촬영을 통해 육안 판정하였고, 판정기준은 시료 처리군 및 대조군을 시료처리전과 비교하여 개선 없음, 약간의 개선, 상당한 개선의 3단계로 판정하여 표 2에 나타내었다.Wrinkle improvement was judged by visual inspection and photographing of the sample treatment area first, and the judgment criteria were judged by three stages of no improvement, slight improvement, and significant improvement compared to the sample treatment group and the control group. Table 2 shows.
[실시예 4 및 비교예 1]Example 4 and Comparative Example 1
1. 피부 주름 개선용 화장료 엣센스의 제조1. Preparation of cosmetic essence for skin wrinkle improvement
하기 표 3과 같은 조성으로 잔토톡솔을 포함하는 피부 주름 개선용 화장료 엣센스의 제형을 실시예 4로 제조하였으며, 상기 실시예 중 잔토톡솔 만을 포함하 지 않는 것을 제외하고는 실시예 4와 동일하게 화장료 엣센스를 제조한 것을 비교예 1로 하였다.To prepare a formulation of the cosmetic essence for improving skin wrinkles including xanthotoxol in the composition as shown in Table 3 in Example 4, except that it does not contain only xanthotoxol in the same manner as in Example 4 What manufactured the essence was made into the comparative example 1.
2. 패널 테스트를 통한 피부 주름 개선 효과 실험2. Experimental effect on skin wrinkle improvement through panel test
상기 실시예 4과 비교예 1의 엣센스에 대해서 건강한 35세에서 50세의 여성을 대상으로 피부 주름개선 효과를 다음과 같이 시험하였다.The skin wrinkle improvement effect of the essence of Example 4 and Comparative Example 1 was tested in healthy 35 to 50 year old women as follows.
35세에서 50세까지의 여성 30명을 15명씩 2개의 군으로 구분하고 1군은 잔토톡솔을 1% 포함하는 실시예 4의 엣센스를, 2군은 비교예 1의 엣센스를 안면부에 1일 1회 3개월간 도포하였다.Thirty females from 35 to 50 years old were divided into two groups of 15 people each, and the first group had an essence of Example 4 containing 1% of xantoxol, and the second group had an essence of Comparative Example 1 on the
3개월 후 피부 주름의 개선정도를 피험자의 설문 및 피부 주름의 영상분석을 통해 평가하였다. 피험자의 설문은 피부 주름개선 및 탄력증진에 관하여 사용전과 비교하여 개선 없음, 약간의 개선, 상당한 개선의 3단계로 판정하였으며 결과는 표 4에 나타내었다. After 3 months, the improvement of skin wrinkles was evaluated by subject's questionnaire and image analysis of skin wrinkles. The subject's questionnaire was judged in three stages of improvement of skin wrinkles and elasticity compared with before use, no improvement, slight improvement, and significant improvement. The results are shown in Table 4.
상기 표 4에서 볼 수 있듯이, 본 발명에 의한 실시예 4의 엣센스를 사용한 경우 피부 주름 개선 효과가 우수함을 알 수 있다.As can be seen in Table 4, it can be seen that the skin wrinkle improvement effect is excellent when using the essence of Example 4 according to the present invention.
3. 영상분석을 통한 주름 개선 효과 실험 3. Experimental effect of wrinkle improvement through image analysis
주름의 영상분석에 의한 평가는 실험이 시작되기 전, 눈 밑의 레플리카(replica)를 채취하고(Xantopren, Bayer), 실험이 종료된 직후 레플리카를 눈밑의 동일 부위에서 채취하여 영상분석을 통해 피부 주름의 2차원적 분석으로 피부 주름의 밀도를 측정하였다. 영상분석에 의한 피부 주름 밀도의 측정 결과는 표 5에 사용 전 피부 주름밀도 대비 사용 후 피부 주름 밀도의 감소율을 평균하여 나타내었다.Image analysis of wrinkles was performed before the start of the experiment (replica) under the eyes (Xantopren, Bayer), and immediately after the end of the experiment, the replica was taken from the same area under the eyes and the skin wrinkles through image analysis The two-dimensional analysis of the skin wrinkle density was measured. The measurement results of skin wrinkle density by image analysis are shown in Table 5 by averaging the decrease rate of skin wrinkle density after use compared to skin wrinkle density before use.
상기 표 5에서 알 수 있듯이, 본 발명에 의한 잔토톡솔을 첨가한 실시예 4의 엣센스를 도포한 경우 피부 주름의 밀도가 비교예 1의 화장료 조성물에 비해 크게 감소하는 것을 알 수 있다.As can be seen in Table 5, when applying the essence of Example 4 with the addition of the xanthotoxol according to the present invention it can be seen that the density of the skin wrinkles is significantly reduced compared to the cosmetic composition of Comparative Example 1.
[실험예] Experimental Example
잔토톡솔의 생체 안전성Biosafety of Xantoxol
이하 잔토톡솔을 포함하는 피부 주름 개선용 화장료 조성물의 제조 실시예 및 비교예를 나타낸다.Hereinafter, the preparation examples and comparative examples of the cosmetic composition for improving skin wrinkles comprising xantoxol are shown.
[실시예 5 및 비교예 2]Example 5 and Comparative Example 2
피부 주름 개선용 피부 외용연고Skin ointment for skin wrinkle improvement
잔토톡솔을 포함하는 피부 주름 개선용 피부 외용연고의 제형을 실시예 5로 제조하였으며, 상기 실시예 중 잔토톡솔 만을 포함하지 않는 것을 제외하고는 실시예 5와 동일하게 화장료 엣센스를 제조한 것을 비교예 2로 하였다. 상세한 조성은 하기 표 6에 나타내었다.Formulation of the skin external ointment for improving skin wrinkles comprising xantoxol was prepared in Example 5, except that the cosmetic essence was prepared in the same manner as in Example 5 except that xantoxol was not included only in the comparative example It was set to two. Detailed compositions are shown in Table 6 below.
[실시예 6 및 비교예 3]Example 6 and Comparative Example 3
피부 주름 개선용 화장료 크림Cosmetic cream for improving skin wrinkles
잔토톡솔을 포함하는 피부 주름 개선용 화장료 크림의 제형을 실시예 6으로 제조하였으며, 상기 실시예 중 잔토톡솔 만을 포함하지 않는 것을 제외하고는 실시예 6과 동일하게 화장료 크림을 제조한 것을 비교예 3으로 하였다. 상세한 조성은 하기 표 7에 나타내었다. Formulation of the cosmetic cream for improving skin wrinkles comprising xantoxol was prepared in Example 6, except that only the xantoxol was not included in the above Example 6 to prepare a cosmetic cream as in Comparative Example 3 It was made. The detailed composition is shown in Table 7 below.
[실시예 7 및 비교예 4]Example 7 and Comparative Example 4
피부 주름 개선용 유연화장수Softener for improving skin wrinkles
잔토톡솔을 포함하는 피부 주름 개선용 유연화장수의 제형을 실시예 7로 제조하였으며, 상기 실시예 중 잔토톡솔 만을 포함하지 않는 것을 제외하고는 실시예 7과 동일하게 유연화장수를 제조한 것을 비교예 4으로 하였다. 상세한 조성은 하기 표 8에 나타내었다.Formulation of the flexible cosmetics for improving skin wrinkles containing xanthoxol was prepared in Example 7, except that the xanthoxol was prepared in the same manner as in Example 7 except that only the xanthoxol is included in Comparative Example 4 It was made. The detailed composition is shown in Table 8 below.
[실시예 9 및 비교예 6]Example 9 and Comparative Example 6
피부 주름 개선용 화장료 팩Cosmetic pack for improving skin wrinkles
잔토톡솔을 포함하는 피부 주름 개선용 화장료 팩의 제형을 실시예 9로 제조하였으며, 상기 실시예 중 잔토톡솔 만을 포함하지 않는 것을 제외하고는 실시예 9 와 동일하게 화장료 팩을 제조한 것을 비교예 6으로 하였다. 상세한 조성은 하기 표 10에 나타내었다.Formulation of the cosmetic pack for improving the skin wrinkles containing xantoxol was prepared in Example 9, except that only the xantox toxol in the above example was manufactured in the same manner as in Example 9 to prepare a cosmetic pack It was made. The detailed composition is shown in Table 10 below.
이상 살펴본 바와 같이, 본 발명의 잔토톡솔을 유효성분으로 포함하는 피부 주름 개선용 화장료 조성물은 피부의 섬유아세포에 대하여 매우 강력한 피부 주름 개선용 화장료 효과를 나타내었으며, 헤어리스 마우스를이용한 피부 주름 개선 효과 시험에 있어서도 매우 우수한 피부 주름 개선 효과를 나타내었다.As described above, the cosmetic composition for improving skin wrinkles comprising the xanthotoxol of the present invention as an active ingredient showed a very powerful cosmetic effect for improving skin wrinkles against fibroblasts of the skin, and a skin wrinkle improving effect using a hairless mouse. The test also showed a very good skin wrinkle improvement.
본 발명의 피부 주름 개선용 화장료 조성물은 생체에 콜라겐 합성 촉진제로서 잔토톡솔(Xanthotoxol: 8-Hydoxypsoralen)을 포함하여 피부의 섬유아세포의 콜라겐합성을 촉진함으로써, 피부의 탄력을 향상시키고, 피부 주름을 개선하는 효과가 매우 우수하다.The cosmetic composition for improving skin wrinkles of the present invention includes xanthotoxol (8-Hydoxypsoralen) as a collagen synthesis promoter in vivo, thereby promoting collagen synthesis of fibroblasts of the skin, thereby improving skin elasticity and improving skin wrinkles. The effect is very good.
Claims (7)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020030081596A KR100769579B1 (en) | 2003-11-18 | 2003-11-18 | Cosmetic composition for improving skin wrinkles |
CNB2004800336572A CN100542527C (en) | 2003-10-17 | 2004-09-21 | Promote synthetic compositions of collagen and the preparation for external application to skin compositions that comprises it |
PCT/KR2004/002418 WO2005037270A1 (en) | 2003-10-17 | 2004-09-21 | Composition for promoting synthesis of collagen, and composition for external preparation for skin comprising the same |
US10/575,974 US20070065377A1 (en) | 2003-10-17 | 2004-09-21 | Composition for promoting synthesis of collagen, and composition for external preparation for skin comprising the same |
JP2006535260A JP4129475B2 (en) | 2003-10-17 | 2004-09-21 | Collagen synthesis promoter and skin external preparation composition containing the same |
US12/405,964 US20090233997A1 (en) | 2003-10-17 | 2009-03-17 | Composition for promoting synthesis of collagen, and composition for external preparation for skin comprising the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020030081596A KR100769579B1 (en) | 2003-11-18 | 2003-11-18 | Cosmetic composition for improving skin wrinkles |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050047801A KR20050047801A (en) | 2005-05-23 |
KR100769579B1 true KR100769579B1 (en) | 2007-10-23 |
Family
ID=37246688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020030081596A KR100769579B1 (en) | 2003-10-17 | 2003-11-18 | Cosmetic composition for improving skin wrinkles |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100769579B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180062759A (en) | 2016-12-01 | 2018-06-11 | (주)골드파파스 | Anti-aging and anti-wrinkle cosmetic composition |
KR20180062756A (en) | 2016-12-01 | 2018-06-11 | (주)골드파파스 | Anti-aging and anti-wrinkle cosmetic composition |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001131050A (en) * | 1999-11-08 | 2001-05-15 | Kanebo Ltd | Skin cosmetic |
-
2003
- 2003-11-18 KR KR1020030081596A patent/KR100769579B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001131050A (en) * | 1999-11-08 | 2001-05-15 | Kanebo Ltd | Skin cosmetic |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180062759A (en) | 2016-12-01 | 2018-06-11 | (주)골드파파스 | Anti-aging and anti-wrinkle cosmetic composition |
KR20180062756A (en) | 2016-12-01 | 2018-06-11 | (주)골드파파스 | Anti-aging and anti-wrinkle cosmetic composition |
Also Published As
Publication number | Publication date |
---|---|
KR20050047801A (en) | 2005-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4572003B2 (en) | Use of peptides for scarring, moisturizing and improving skin appearance as cosmetics or as dermatological agents during natural aging or hyperaging (sun dermatitis, contamination) | |
JP4117773B2 (en) | Cosmetic or dermatological composition comprising a combination of an elastase inhibitor of the N-acylaminoamide family and at least one antifungal agent or at least one antibacterial agent | |
KR101418986B1 (en) | Composition for promoting collagen synthesis and cosmetics comprising the same | |
US20090233997A1 (en) | Composition for promoting synthesis of collagen, and composition for external preparation for skin comprising the same | |
KR101418979B1 (en) | Composition for accelerating collagen formation and cosmetics using the same | |
KR100769579B1 (en) | Cosmetic composition for improving skin wrinkles | |
KR100769577B1 (en) | Cosmetic composition for improving skin wrinkles | |
JPH10167957A (en) | Intercellular adhesion suppressing agent | |
KR100769578B1 (en) | Cosmetic composition for improving skin wrinkles | |
KR101145814B1 (en) | Composition for improving skin wrinkle | |
KR101897570B1 (en) | Composition for anti-wrinkle comprising handroanthus impetiginosus extract and method for preparing the extract | |
JP2009102378A (en) | Pharmaceutical agent for pruritus, rough skin, sensitive skin and whitening by suppressing production/release of stem cell factor | |
KR100467501B1 (en) | A cosmetic composite | |
JPH06271446A (en) | Wrinkle improver | |
KR102204367B1 (en) | Cosmetic compositions for improving skin wrinkle | |
KR20050037107A (en) | Cosmetic composition against aging of the skin | |
KR20050037106A (en) | Composition for wound healing | |
KR101526592B1 (en) | Composition for improving skin wrinkles | |
KR100834697B1 (en) | Cosmetic or pharmaceutical composition containing medicinal herb, cypress or apple extract | |
WO1995027474A1 (en) | Dermatologic preparation | |
JP2002284666A (en) | Cosmetics | |
JP3215534B2 (en) | External preparation for skin | |
JP3160415B2 (en) | Wrinkle improver and keratosis improver | |
KR101582652B1 (en) | Cosmetic coposition for improvement of Wrinkle | |
JP2001122729A (en) | Cosmetic for sensitive skin having anti-inflammatory effect |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20031118 |
|
PG1501 | Laying open of application | ||
A201 | Request for examination | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20060524 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20031118 Comment text: Patent Application |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20070509 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20071010 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20071017 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20071018 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
G170 | Re-publication after modification of scope of protection [patent] | ||
PG1701 | Publication of correction | ||
PR1001 | Payment of annual fee |
Payment date: 20100927 Start annual number: 4 End annual number: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20110915 Start annual number: 5 End annual number: 5 |
|
FPAY | Annual fee payment |
Payment date: 20120914 Year of fee payment: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20120914 Start annual number: 6 End annual number: 6 |
|
FPAY | Annual fee payment |
Payment date: 20130913 Year of fee payment: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20130913 Start annual number: 7 End annual number: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140917 Year of fee payment: 8 |
|
PR1001 | Payment of annual fee |
Payment date: 20140917 Start annual number: 8 End annual number: 8 |
|
FPAY | Annual fee payment |
Payment date: 20150917 Year of fee payment: 9 |
|
PR1001 | Payment of annual fee |
Payment date: 20150917 Start annual number: 9 End annual number: 9 |
|
FPAY | Annual fee payment |
Payment date: 20160919 Year of fee payment: 10 |
|
PR1001 | Payment of annual fee |
Payment date: 20160919 Start annual number: 10 End annual number: 10 |
|
FPAY | Annual fee payment |
Payment date: 20170928 Year of fee payment: 11 |
|
PR1001 | Payment of annual fee |
Payment date: 20170928 Start annual number: 11 End annual number: 11 |
|
FPAY | Annual fee payment |
Payment date: 20180927 Year of fee payment: 12 |
|
PR1001 | Payment of annual fee |
Payment date: 20180927 Start annual number: 12 End annual number: 12 |
|
FPAY | Annual fee payment |
Payment date: 20191014 Year of fee payment: 13 |
|
PR1001 | Payment of annual fee |
Payment date: 20191014 Start annual number: 13 End annual number: 13 |
|
PR1001 | Payment of annual fee |
Payment date: 20200925 Start annual number: 14 End annual number: 14 |
|
PR1001 | Payment of annual fee |
Payment date: 20210929 Start annual number: 15 End annual number: 15 |
|
PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20230728 |